[Pazopanib (Votrient) for the treatment of patients with advanced renal cell carcinoma]
Comite d'Avaluacio de Medicaments d'Utilitzacio Hospitalaria (CAMUH)
Record ID 32011000226
Catalan
Authors' objectives:
To analyze the available scientific evidence on the efficacy, safety and efficiency of pazopanib in patients with advanced RCC.
Authors' recommendations:
The results show that pazopanib, compared to placebo, increases progression-free survival both in patients previously treated with cytokines as well as in naive patients. However, the analyses carried out showed that such increase was higher in patients who had not been previously treated with cytokines. This notwithstanding, it must be noted that the use of placebo as comparator is not considered to be adequate as here are other treatment alternatives such as for instance sunitinib. Pazopanib is well tolerated and no differences were found regarding patient quality of life.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.gencat.cat/salut/depsan/units/aatrm/pdf/pazopanib_carcinoma_renal_aiaqs2011ca.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Pyrimidines
- Spain
- Sulfonamides
Contact
Organisation Name:
Agencia de Qualitat i Avaluacio Sanitries de Catalunya
Contact Address:
Antoni Parada, CAHTA, Roc Boronat, 81-95 (2nd floor), 08005 Barcelona, Spain, Tel. +34 935 513 928, Fax: +34 935 517 510
Contact Name:
direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Contact Email:
direccio@aatrm.catsalut.net / aparada@aatrm.catsalut.net
Copyright:
Catalan Agency for Health Information, Assessment and Quality (CAHIAQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.